CRISPR Therapeutics AG Stock Forecast

Stock Price Forecast

According to 22 analysts polled by S&P Global, CRISPR Therapeutics AG stock has a consensus rating of "Buy" and an average price target of $87.56. The average 1-year stock price forecast is 51.70% higher than the current stock price, while the lowest is $44 (-23.77%) and the highest is $291 (+404.16%).

Price Target: $87.56 (+51.70%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$44	$87.56	$80	$291
Change	-23.77%	+51.70%	+38.60%	+404.16%

Analyst Ratings

The average analyst rating for CRISPR Therapeutics AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	12	13	11	10	9	8
Buy	5	4	4	5	4	5
Hold	9	9	9	10	9	9
Sell	0	0	0	0	0	0
Strong Sell	1	1	1	0	0	0
Total	27	27	25	25	22	22

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Sami Corwin William Blair	William Blair	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Aug 29, 2026
Maxwell Skor Morgan Stanley	Morgan Stanley	Hold Maintains $60	Hold	Maintains	$60	+3.95%	Aug 28, 2026
Salveen Richter Goldman Sachs	Goldman Sachs	Hold Reiterates $48 → $55	Hold	Reiterates	$48 → $55	-4.71%	Aug 10, 2026
Alec Stranahan Bank of America Securities	Bank of America Securities	Buy Reiterates $83 → $82	Buy	Reiterates	$83 → $82	+42.07%	Aug 5, 2026
Yanan Zhu Wells Fargo	Wells Fargo	Hold Maintains $75	Hold	Maintains	$75	+29.94%	Aug 5, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

40.83M

from 3.51M

1,063.30%

from 3.51M

Revenue Next Year

156.58M

from 40.83M

283.48%

from 40.83M

EPS This Year

-4.45

from -6.47

EPS Next Year

-3.50

from -4.45

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	914.96M	1.20M	371.21M	37.31M	3.51M	40.83M
Revenue Growth	127,154.94%	-99.87%	30,885.48%	-89.95%	-90.59%	1,063.30%
Operating Income	373.53M	-673.16M	-222.54M	-466.57M	-568.32M	-508.76M
Net Income	377.66M	-650.18M	-153.61M	-366.25M	-581.60M	-432.41M
EPS	-	-	-	-	-6.47	-4.45
Free Cash Flow	284.82M	-337.58M	-238.97M	-29.27M	-205.62M	-419.94M
No. Analysts	-	-	-	-	-	17

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	164.3M
Avg	40.8M
Low	11.6M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	4,581.7%
Avg	1,063.3%
Low	231.6%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-3.19
Avg	-4.45
Low	-5.84

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-